Abstract
Mirabegron is widely considered as an effective and safe drug for patients with overactive bladder (OAB). However, there is no evidence regarding the efficacy of mirabegron in human T cell lymphotropic virus-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients with OAB symptoms. The aim of the present study was to clarify the efficacy of mirabegron in HAM/TSP patients with OAB symptoms. The present study evaluated the efficacy of mirabegron treatment (50 mg, once daily) in nineteen HAM/TSP patients with OAB symptoms by assessing subjective symptoms using the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) before and 12 weeks after administration. Voided volume (VV), maximum flow rate (Qmax ), and post-void residual (PVR) urine volume were evaluated as objective symptoms. Mirabegron treatment improved OABSS in terms of night-time frequency, urgency, and total score (P < .001). In addition, on the IPSS, mirabegron therapy improved urgency, nocturia, storage symptoms (Questions 2, 4 and 7 on the IPSS), as well as the total score (P < .001). The quality of life (QoL) on the IPSS also improved after treatment (P < .001). However, there were no significant changes i...Continue Reading
References
May 3, 1986·Lancet·M OsameM Tara
May 1, 1993·AIDS Research and Human Retroviruses·G de Thé, R Bomford
Apr 22, 1993·The New England Journal of Medicine·P Höllsberg, D A Hafler
Mar 13, 2001·Annual Review of Immunology·M Yoshida
May 8, 2007·Urology·Néviton M CastroEdgar M Carvalho
May 10, 2007·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Neviton M CastroEdgar M Carvalho
May 17, 2007·Clinics·Paulo OliveiraEdgar M Carvalho
Feb 9, 2008·Journal of the Neurological Sciences·Mariana Garcia CrodaJorge Casseb
Jul 5, 2008·European Urology·Christopher R ChappleDavid Weinstein
Apr 18, 2009·Urology·Kikuo OkamuraChikako Tange
Apr 9, 2010·Oral Diseases·F M MartinsK L Ortega
Feb 5, 2011·Postgraduate Medicine·James P Capo'Weizhong He
Apr 19, 2012·Arquivos de neuro-psiquiatria·Davi Tanajura CostaMarshall Jay Glesby
Nov 20, 2012·Frontiers in Microbiology·Yoshihisa Yamano, Tomoo Sato
Nov 28, 2012·European Urology·Vik KhullarChristopher Chapple
Dec 1, 2012·European Urology·Christopher R ChappleNancy Martin
Jan 22, 2013·European Urology·Adrian WaggGerhard Compion
Jul 26, 2014·Drugs·Mark Sanford
Aug 6, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Christopher R ChappleVik Khullar
Sep 18, 2014·Revista Da Sociedade Brasileira De Medicina Tropical·José Abraão Carneiro NetoEdgar Marcelino de Carvalho
Nov 6, 2015·BMC Musculoskeletal Disorders·Hideki NakamuraAtsushi Kawakami
May 27, 2016·Orphanet Journal of Rare Diseases·Ariella L G Coler-ReillyYoshihisa Yamano
Jul 31, 2016·BMC Urology·Tomohiro MatsuoHideki Sakai
Dec 8, 2016·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Daniela Assis do ValeKarem López Ortega
Citations
Dec 6, 2019·World Journal of Urology·Elie El HelouElie Nemr
Jul 15, 2021·IJU Case Reports·Tomohiro MatsuoHideki Sakai
Aug 11, 2021·Orphanet Journal of Rare Diseases·Naoki IijimaYoshihisa Yamano